Manju Dawkins, MD, discusses Skin Angels, why clinicians belong in dermatology innovation, and her work to reduce injection pain and needle anxiety.
|Videos|June 6, 2017
Ingrezza for Tardive Dyskinesia: Its Safety, Efficacy, and Implication
Author(s)Kevin Kunzmann
Laxman Bahroo, DO, explains how no treatment has shown more efficacy for Tardive Dyskinesia against placebo than valbenazine (Ingrezza), and how its approval changes the scope of the movement disorder.
Advertisement
Laxman Bahroo, DO, director of the Botulinum Toxin Clinic and associate professor of Neurology at Georgetown University Hospital, took time out of the 21st International Congress of Parkinson's Disease and Movement Disorders to discuss Ingrezza, the first and only treatment approved for Tardive Dyskinesia.
Advertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.
In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.
Advertisement
Advertisement
Trending on HCPLive
1
The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH
2
Anti-Alpha-Gal Antibodies Block IgE Binding in Alpha-Gal Syndrome
3
Nearly 9 in 10 US Adults With CKD Don't Know They Have It, With Pranav Garimella
4
Weekly Insulin Efsitora Alfa (Onswik) Gains FDA approval for Type 2 Diabetes
5